Roles
- Professor of Clinical Medicine
-
Biography
Dr. Amer Beitinjaneh is a Professor of Clinical Medicine at the University of Miami Miller School of Medicine and a nationally recognized hematologist-oncologist specializing in hematopoietic stem cell transplantation, CAR T-cell therapy, and complex hematologic malignancies. With more than 15 years of experience, his clinical and research work focuses on advancing novel cellular and immune-based therapies for patients with high-risk and relapsed hematologic malignancies include leukemia, lymphoma, and Multiple Myeloma.
Dr. Beitinjaneh leads the Transplantation and Cellular Therapy Site Disease Group at Sylvester Comprehensive Cancer Center and serves as the institutional Principal Investigator for the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). He has led numerous investigator-initiated, federally funded, and industry-sponsored clinical trials, including first-in-human and early-phase studies. His expertise includes clinical trial design, therapeutic development, efficacy and safety evaluation, and multicenter research collaboration.
He has authored or co-authored more than 100 peer-reviewed publications and serves currently on national and international committees, including ASTCT, CIBMTR, EBMT, and BMT CTN. A Foundation for the Accreditation of Cellular Therapy (FACT) inspector for over a decade, he contributes to clinical practice standards, quality assessment, and patient safety in transplantation and cellular therapy. His expertise also encompasses evidence-based clinical decision-making and management of complex treatment-related complications.
Dr. Beitinjaneh directs the University of Miami Cellular Therapy and Stem Cell Transplantation Fellowship and serves as Site Director at Sylvester Comprehensive Cancer Center for ACGME-accredited Hematology/Oncology Fellowship programs affiliated with Broward Health North and Cleveland Clinic Florida. He has also served on the American Board of Internal Medicine (ABIM) Hematology Item-Writing Committee and contributes to ASTCT education and practice guideline initiatives.
His academic interests include novel therapeutic development, clinical trial innovation, and improving safety and outcomes in transplantation and cellular immunotherapy. -
Education & Training
Education
Post Graduate Training
Licensures and Certifications
-
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Articles & News
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 17 clinical trials.
-
An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia
- Principal Investigator: Amer Beitinjaneh
- Study Phase: Phase 1/Phase 2
- Enrollment Status: Closed
-
This is an expanded access protocol that will be conducted at sites qualified and approved to treat subjects with lisocabtagene maraleucel. Sometimes when lisocabtagene maraleucel is manufactured the drug does not pass all the testing results to be called lisocabtagene maraleucel. When this happens the drug is called nonconforming lisocabtagene maraleucel. The expanded access protocol will be used to allow subjects to receive nonconforming lisocabtagene maraleucel only if the potential benefit is better than the potential risk. This expanded access protocol is restricted to those subjects who were prescribed lisocabtagene maraleucel as part of their routine care.Subjects will first receive a lymphodepleting chemotherapy regimen and then be treated with nonconforming lisocabtagene maraleucel as the treatment plan.
- Principal Investigator: Amer Beitinjaneh
- Study Phase: N/A
- Enrollment Status: Not Accepting
-
Expanded Access Protocol for Providing Tabelecleucel to Patients With Epstein-Barr Virus-Associated Viremia or Malignancies for Whom There Are No Appropriate Alternative Therapies
- Principal Investigator: Amer Beitinjaneh
- Study Phase: N/A
- Enrollment Status: Closed
-
A Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Relapsed or Refractory T or B Cell Malignancies
- Principal Investigator: Amer Beitinjaneh
- Study Phase: Phase 1
- Enrollment Status: Closed
-
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma
- Principal Investigator: Amer Beitinjaneh
- Study Phase: Phase 2
- Enrollment Status: Closed
-
The purpose of this clinical study is to determine if LYL797, the study drug, made up of a participants own immune cells that are genetically engineered, is safe at different doses and is able to kill tumor cells.
- Principal Investigator: Amer Beitinjaneh
- Study Phase: Phase I
- Enrollment Status: Closed
-
The purpose of this study is to research the safety and effectiveness of increasing doses of CD4CAR T cell therapy. Researchers will evaluate up to 4 different dose levels of CD4CAR T cells. They will study what side effects occur with these dose levels and will evaluate how effective the dose levels are at treating cancer in the participants in this study.
- Principal Investigator: Amer Beitinjaneh
- Study Phase: Phase I
- Enrollment Status: Not Accepting
-
1630GCC: A Pilot Study of Zydelig in Patients With B-cell Malignancies as Post-Autologous Transplant Remission Maintenance
- Principal Investigator: Amer Beitinjaneh
- Study Phase: Phase 2
- Enrollment Status: Closed
-
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
- Principal Investigator: Amer Beitinjaneh
- Study Phase: Phase 3
- Enrollment Status: Not Accepting
-
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
- Principal Investigator: Amer Beitinjaneh
- Study Phase: Phase 3
- Enrollment Status: Not Accepting
-
The purpose of this study is to research the safety and effectiveness of CD4CAR T cell therapy in patients with relapsed or refractory (has not responded to treatment) CD4+ lymphoma or leukemia. Researchers will collect information about side effects that participants experience, and information related to how participants cancer responds to therapy. Researchers will study increasing doses to find the highest dose that does not result in unacceptable side effects.
- Principal Investigator: Amer Beitinjaneh
- Study Phase: Phase I
- Enrollment Status: Not Accepting
-
Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy
- Principal Investigator: Amer Beitinjaneh
- Study Phase: Phase 3
- Enrollment Status: Open
-
The purpose of this study is to research the safety and effectiveness of increasing doses of CD4CAR T cell therapy. Researchers will evaluate up to 4 different dose levels of CD4CAR T cells. They will study what side effects occur with these dose levels and will evaluate how effective the dose levels are at treating cancer in the participants in this study.
- Principal Investigator: Amer Beitinjaneh
- Study Phase: Phase I
- Enrollment Status: Not Accepting
-
The purpose of this study is to learn about the effectiveness and safety of a new study drug called AFM13 when used in combination with a new cell therapy called AB-101. The study will also look at how the body processes this combination of drugs (called pharmacokinetics”).
- Principal Investigator: Amer Beitinjaneh
- Study Phase: Phase II
- Enrollment Status: Closed
-
High-dose chemotherapy followed by blood stem cell transplantation is administered to lymphoma patients with an intention to cure. However, high-dose chemotherapy simultaneously causes damage to healthy tissues that frequently result in severe complications that lead to hospitalization and can be life threatening. These severe complications involve the blood, immune, gastro-intestinal systems, and other vital organs.The purpose of this study is to determine if experimental therapy AB-205 (study drug) can prevent or reduce the occurrence and duration of the severe chemotherapy related complications when compared to placebo in patients with lymphoma undergoing treatment with high-dose chemotherapy and blood stem cell transplantation. All patients, whether treated with AB-205 or placebo, will receive standard preventive and supportive care therapies.
- Principal Investigator: Amer Beitinjaneh
- Study Phase: Phase III
- Enrollment Status: Closed
-
The primary objective of the Phase III portion of the trial is to compare GVHD-free survival (GFS) up to 24 months after hematopoietic cell transplantation (HCT) between the two GVHD prophylaxis regimens. An event for this time-to-event outcome is defined as Grade III-IV acute GVHD, chronic GVHD requiring systemic immune suppression, or death by any cause.
- Principal Investigator: Amer Beitinjaneh
- Study Phase: Phase III
- Enrollment Status: Open
-
A Phase 1b, single arm study to evaluate the safety and efficacy of the combination therapy, CD30.CAR-T and the programmed cell death protein-1(PD-1) checkpoint inhibitor, nivolumab.To assess preliminary evidence of anti-tumor activity using CR rate of autologous CD30.CAR-T in combination with nivolumab, at EOT (after4treatmentcycles of nivolumab and a single infusion of CD30.CAR-T) using the Lugano Classification Revised Staging System for malignant lymphoma.
- Principal Investigator: Amer Beitinjaneh
- Study Phase: Phase I
- Enrollment Status: Closed